COVID-19 Command Center Analytics Platform To Facilitate Clinical Research Efforts – Saama and iNDX.Ai Case Study

0
919

Data analytics and related technologies have reliable capabilities to assist the research on the novel coronavirus and can expedite the clinical development efforts taken to stop the virus behind the pandemic.

The COVID-19 Command Center analytics platform is a combination of Saama’s Life Science Analytics Cloud (LSAC) and iNDX.Ai’s iCore Platform. It was created to provide analytics platform support to all the in-house Covid-19 clinical researches happening.

“Saama wants all life science companies, whether they are engaged in public or private research efforts, to have access to the best possible analytics platform so they can expedite promising COVID-19 clinical trials and bring critical vaccines and treatments to the market as soon as possible,” said Suresh Katta, Founder and CEO of Saama Technologies. “The COVID-19 Command Center, the first offering from Saama’s purpose-built Command Center strategy, is customized to meet immediate needs related to research on the novel coronavirus, but can also be used more broadly for other infectious disease clinical development efforts now and in the future.”

Last month, Saama Technologies announced their collaboration with iNDX.Ai with the intention to harness the COVID-19 data shared in EndPandemic National Data Consortium to speed the research efforts to find a cure. The COVID-19 Command Center includes patient data from ongoing COVID-19 clinical trials in China, South Korea, and the U.S. with nearly 8,500 patients, including over 3,000 positive cases.

The COVID-19 Command Center, AI-powered data analytics platform delivers all multiomics and clinical data analytics needed to conduct COVID-19 studies.From preclinical development to approval, researchers can optimize study design, patient selection, site activation and scientific analysis by dynamically visualizing, analyzing, and interrogating data faster than ever before.

Mohan Uttarwar, CEO of iNDX.Ai, believes that AI-enabled deep data analytics will facilitate biopharma companies to speed up their clinical trials to deliver therapies that could potentially treat and prevent COVID-19.“The COVID-19 Command Center ensures that every life science company, whether engaged in solo or collaborative research, will be able to apply state-of-the-art data analytics to inform and advance their research and help end the pandemic. By partnering on the COVID-19 Command Center, iNDX.Ai and Saama provide an end-to-end clinical development solution, from in silico biomarker discovery to Investigational New Drug (IND) application submission.”

When the world gets an alarming call due to the pandemic, it gets awakened only to understand that AI powered data analytics is the only tool to snooze and to even stop the alarm.